Loading company…
Seoul biotech company making patient-derived organoids for drug testing, molecular diagnostics and personalized treatment.
Founded in 2018 and headquartered in Seoul, South Korea, Next&Bio develops patient-derived organoids used for drug testing and molecular diagnostics, aimed at personalized treatment. Its clients include biotech firms, research institutions and healthcare providers. In April 2020 the company raised KRW 6.5 billion in Series A funding from HK Inno.N Corporation and Hyundai Investment Partners to expand its contract research services. CEO Hyeon-sook Lee leads the company.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in